**Background of SDC3 Antibody**
Syndecan-3 (SDC3) is a transmembrane heparan sulfate proteoglycan belonging to the syndecan family, which plays critical roles in cell adhesion, migration, and signaling by interacting with extracellular matrix components, growth factors, and cytoskeletal proteins. Predominantly expressed in the nervous system, adipose tissue, and developing organs, SDC3 is implicated in neural development, synaptic plasticity, and energy metabolism regulation. Its extracellular domain binds ligands like growth factors and cytokines, modulating pathways such as Wnt and FGF signaling, while its cytoplasmic domain interacts with cytoskeletal regulators, influencing cell behavior.
SDC3 antibodies are essential tools for studying its expression, localization, and function in physiological and pathological contexts. Research highlights SDC3's dual role in cancer, acting as a tumor suppressor or promoter depending on the tissue type. In neurodegenerative diseases, SDC3 regulates amyloid-beta aggregation and tau phosphorylation, suggesting potential therapeutic targets. Additionally, SDC3 is linked to obesity and metabolic disorders due to its role in adipocyte differentiation and insulin signaling.
Antibodies targeting SDC3 (polyclonal or monoclonal) are widely used in techniques like immunohistochemistry, Western blotting, and flow cytometry. Recent studies also explore SDC3's involvement in immune responses and tissue repair, emphasizing its versatility as a biomarker or therapeutic candidate. Ongoing research continues to unravel SDC3's complex mechanisms, driving demand for high-specificity antibodies to advance diagnostic and therapeutic innovations.